The current status of erythromycin, kanamycin, novobiocin, oleandomycin, ristocetin, and vancomycin, with particular reference to their use in staphylococcal disease; panel discussion.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular; D003879:Dermatologic Agents; D004917:Erythromycin; D007612:Kanamycin; D008837:Micrococcus / Q000472:pathogenicity* / Q000628:therapy*; D009675:Novobiocin; D009827:Oleandomycin; D012310:Ristocetin; D013203:Staphylococcal Infections; D014640:Vancomycin
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D003879:Dermatologic Agents; D012310:Ristocetin; D009675:Novobiocin; D007612:Kanamycin; D004917:Erythromycin; D014640:Vancomycin; D009827:Oleandomycin
ANTIBIOTICS/therapeutic use; MICROCOCCAL INFECTIONS/therapy